Recent News

• 06.10.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 06.09.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 06.08.2026 - Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
• 05.29.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 05.29.2026 - Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
• 05.28.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 05.15.2026 - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
• 05.14.2026 - Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
• 05.07.2026 - Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
• 05.05.2026 - Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Recent Filings

• 06.01.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.01.2026 - EX-99.1 EX-99.1
• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.11.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.11.2026 - EX-99.1 EX-99.1
• 04.29.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.21.2026 - EX-99.1 EX-99.1